Ratings TerrAscend Corp.

Equities

TSND

CA88105E1088

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
2.4 ^CAD	-2.44%		+10.09%	+9.09%

Apr. 24	Terrascend Corp. Launches Legend Mini Pre-Roll Packs in New Jersey	CI
Mar. 14	Transcript : TerrAscend Corp., 2023 Earnings Call, Mar 14, 2024

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Over the last twelve months, the sales forecast has been frequently revised upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company sustains low margins.
The group shows a rather high level of debt in proportion to its EBITDA.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Drug Retailers

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TERRASCEND CORP.	+9.09%	521M		-
GREEN THUMB INDUSTRIES INC.	+21.72%	3.17B		D+
GLASS HOUSE BRANDS INC.	+97.67%	674M		-
HIGH TIDE INC.	+38.97%	174M		-
MARIMED INC.	+8.41%	115M		-
CANTOURAGE GROUP SE	+3.76%	104M	-	-
NOVA CANNABIS INC.	+51.69%	55.83M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes